<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en">
	<id>https://wikimd.com/index.php?action=history&amp;feed=atom&amp;title=Atibeprone</id>
	<title>Atibeprone - Revision history</title>
	<link rel="self" type="application/atom+xml" href="https://wikimd.com/index.php?action=history&amp;feed=atom&amp;title=Atibeprone"/>
	<link rel="alternate" type="text/html" href="https://wikimd.com/index.php?title=Atibeprone&amp;action=history"/>
	<updated>2026-04-21T01:49:26Z</updated>
	<subtitle>Revision history for this page on the wiki</subtitle>
	<generator>MediaWiki 1.44.2</generator>
	<entry>
		<id>https://wikimd.com/index.php?title=Atibeprone&amp;diff=5368852&amp;oldid=prev</id>
		<title>Prab: CSV import</title>
		<link rel="alternate" type="text/html" href="https://wikimd.com/index.php?title=Atibeprone&amp;diff=5368852&amp;oldid=prev"/>
		<updated>2024-03-06T04:31:11Z</updated>

		<summary type="html">&lt;p&gt;CSV import&lt;/p&gt;
&lt;p&gt;&lt;b&gt;New page&lt;/b&gt;&lt;/p&gt;&lt;div&gt;[[File:Atibeprone.png|thumb|{{PAGENAME}}]]&amp;lt;br&amp;gt;&amp;#039;&amp;#039;&amp;#039;Atibeprone&amp;#039;&amp;#039;&amp;#039; is a [[pharmacological]] drug that was developed in the late 20th century. It is classified as an [[antidepressant]], specifically a [[non-selective monoamine reuptake inhibitor]]. &lt;br /&gt;
&lt;br /&gt;
== History ==&lt;br /&gt;
&lt;br /&gt;
[[Atibeprone]] was first synthesized in the 1970s by the pharmaceutical company [[Upjohn]]. It was part of a series of compounds developed in an attempt to create a new class of antidepressants. However, despite showing promise in early [[clinical trials]], Atibeprone was never marketed.&lt;br /&gt;
&lt;br /&gt;
== Pharmacology ==&lt;br /&gt;
&lt;br /&gt;
Atibeprone acts by inhibiting the reuptake of [[monoamines]], a group of neurotransmitters that includes [[serotonin]], [[norepinephrine]], and [[dopamine]]. By blocking the reuptake of these neurotransmitters, Atibeprone increases their concentration in the synaptic cleft, enhancing neurotransmission and leading to an improvement in mood.&lt;br /&gt;
&lt;br /&gt;
== Clinical Trials ==&lt;br /&gt;
&lt;br /&gt;
In early clinical trials, Atibeprone showed promise as an antidepressant. It was found to be effective in reducing symptoms of depression and had a favorable side effect profile. However, further development of the drug was halted for unknown reasons, and it was never marketed.&lt;br /&gt;
&lt;br /&gt;
== Side Effects ==&lt;br /&gt;
&lt;br /&gt;
The side effects of Atibeprone are similar to those of other non-selective monoamine reuptake inhibitors. These can include [[nausea]], [[dizziness]], [[insomnia]], and [[anxiety]]. In rare cases, Atibeprone may also cause [[serotonin syndrome]], a potentially life-threatening condition characterized by agitation, hallucinations, rapid heartbeat, and high body temperature.&lt;br /&gt;
&lt;br /&gt;
== Current Status ==&lt;br /&gt;
&lt;br /&gt;
Despite its initial promise, Atibeprone is not currently available for use. The reasons for this are not entirely clear, but may relate to the drug&amp;#039;s side effect profile, difficulties in manufacturing, or a lack of commercial interest.&lt;br /&gt;
&lt;br /&gt;
[[Category:Antidepressants]]&lt;br /&gt;
[[Category:Monoamine reuptake inhibitors]]&lt;br /&gt;
[[Category:Abandoned drugs]]&lt;br /&gt;
{{pharmacology-stub}}&lt;/div&gt;</summary>
		<author><name>Prab</name></author>
	</entry>
</feed>